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ABSTRACT 
Effects of Select Vitamin E Isoforms on the Production of Polyunsaturated Fatty Acid 
Metabolites in Colorectal Cancer 
by 
Martha Akuorkor Borketey 
 
Vitamin E exhibits anti-tumor activity by regulating pathways in cancer cells, potentially 
the lipoxygenase (LOX) pathway.   We studied the effects of alpha tocopherol (AT), 
gamma tocopherol (GT), gamma tocotrienol (GT3), and an alpha-gamma tocopherol 
mixture (ATGT) on the production of the LOX metabolites 13-hydroxyoctadecaenoic 
acid (HODE), 15-hydroxyeicosatetraenoic acid (HETE), 12-HETE, and 5-HETE in 
colorectal cancer.  These metabolites were examined in the HCT-116 cell line after 24 h 
treatment with select vitamin E isoforms and quantified by LC/MS/MS.  Under 
physiological conditions, we find that treatment with varying vitamin E isoforms have 
different effects on the production of 13-HODE, 15-HETE, 12-HETE, and 5-HETE.  GT 
increases 13-HODE and decreases 12-HETE.  AT reverses the effects of GT regulation 
on the LOX pathway, while GT3 has no significant effect on the metabolites tested.  GT 
shows superiority in regulating the LOX pathway as it increases 13-HODE and 
decreases 12-HETE for possible prevention of colorectal cancer.  
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CHAPTER 1 
INTRODUCTION 
Mechanisms of Cancer Development 
Cancer is a disease consisting of a mass of cells that grow and divide faster than 
normal cells of the corresponding tissue type. Some features of cancer cells include the 
fact that they are poorly differentiated compared with normal cells.  Cancer cells also 
have the ability to metastasize as compared to normal cells which are confined to their 
position within an organ by cell adhesion molecules1.  
 The development of cancer involves multiple processes which are marked by 
four successive stages: initiation, promotion, progression and malignancy2.  The first 
stage, initiation, often occurs as a result of continual deoxyribonucleic acid (DNA) 
damage by reactive oxygen species (ROS) such as hydrogen peroxide, superoxide 
radicals, and hydroxyl radicals.  These ROS are produced by exogenous and 
endogenous sources such as environmental pollutants, radiation (e.g. X-rays, ultraviolet 
light (UV) light and gamma rays), metals (i.e. by Fenton reactions), activation of 
inflammatory cells (e.g. macrophages and neutrophils), cytochrome P450 enzyme 
etc2,3,4.  Mutations to genes can result in the formation of oncogenes and the loss of 
function of tumor suppressor genes5 which may be prevented, in part, by antioxidant 
intake.  Tumor suppressor genes are genes that hinder the proliferation of cells.  
Malfunction or inactivation of these genes can promote carcinogenesis6.  Inactivation of 
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tumor suppressor genes occurs through mechanisms such as point mutations (change 
of a single nucleotide in DNA) or deletions7.   
Oncogenes are genes that are formed as a result of mutations in proto-
oncogenes (i.e. proteins that regulate cell proliferation)8.  Oncogenes can be activated 
by mechanisms such as gene amplification (i.e. production of several copies of a gene 
due to continuous replication of a section of the DNA), point mutation and chromosome 
rearrangements or translocations (i.e. attachment of a section of chromosome to a 
different chromosome)9,7.  These mutations cause proto-oncogenes to be more highly 
expressed in cells than normal which enhance carcinogenesis10,1,11. 
Promotion, the second stage of cancer development, involves proliferation of the 
altered cells to produce benign tumors resulting from group of compounds called 
promoters2.  Progression and malignant stages in carcinogenesis occur when some of 
these benign tumors further develop to form invasive tumors7,2.    
Carcinogenesis occurs due to a malfunctioning of genes that usually regulate the 
growth and proliferation of cells which leads to continual progression of the cell 
cycle7.   Alterations of genes that control the checkpoints of the cell cycle from Gap1 
(G1) to S (DNA synthesis) or from Gap 2 (G2) to Mitotic (M) phase may cause cells to 
rapidly divide (enhance cell proliferation) or may cause cells to refuse to undergo 
apoptosis.  Mutations in these checkpoint genes arise in many human cancers12.  These 
genes include cyclins, retinoblastoma gene (RB), p53 gene, cyclin-dependent kinases 
(cdks)7, etc.  
18 
 
Cyclin-dependent kinase 4 (Cdk4) and cyclin D1 complex (proto-oncogenes) are 
also genes that control the G1 phase.  These genes phosphorylate RB causing the 
continuation of the cell cycle in normal cells1.  The over expression of cyclin D1 or Cdk4 
enhance cell proliferation and are observed in various human cancer cells including 
breast cancer13.   
RB is a tumor suppressor gene that is hypophosphorylated in the initial stages of 
G1 and bonds to E2F proteins, nullifying E2F activity by joining to promoter genes in 
which the E2F/DP complex bind.  The E2F/DP complex regulates proteins involved in 
the development of the cell cycle such as cyclins and cdks.  When RB is 
hypophosphorylated, it inhibits the untimely production of genes that control the cell 
cycle1, 7 and allows for DNA replication.  Functional RB protects the fidelity of the DNA 
by preventing DNA replication of mutated DNA.  Dysfunction of the RB gene results in 
replication of mutated DNA which creates genetic instability and allows for uncontrolled 
cell proliferation in several cancers13.  Defects in the RB gene in germ line cells can also 
cause familial RB cancers7. 
The p53 gene is another tumor suppressor gene which functions as a pro-
apoptotic gene by preventing multiple mutations from being integrated into DNA, by up-
regulating apoptotic proteins that cause the death of the cells when severe DNA 
damage occurs1.  Malfunctioning of the tumor suppressor gene p53 prevents apoptosis 
from occurring and leads to an increase in mutations, which enhances the development 
of cancer.  Apoptosis is a process that allows organisms to control the number of cells 
in a tissue by removing cells that are aged or damaged12.  The significance of apoptosis 
19 
 
in the development of cancer is observed when mutated cells continue to proliferate 
instead of dying12.  The refusal of cancer cells to undergo apoptosis plays a significant 
role in the progression of tumors14.  
The p16 gene is a tumor suppressor gene whose function is to hinder the 
continuation of the cell cycle when cells are damaged by inhibiting the activity of cyclin 
D1 and Cdk4 complex.  A defect in the p16 gene is observed in many human cancers.  
Mutations in other genes (e.g. p15 and p18) that inhibit the production of cyclin D1 and 
Cdk4 complex are also observed in various human cancers13,12.  However, over 
expression of B-cell lymphoma 2 (bcl-2) protein, an anti-apoptotic protein, impedes 
apoptosis and enhances the survival of cancer cells1.   
Carcinogenesis may also occur as a result of poor differentiation of cells.  Cell 
differentiation is the process by which specialized cells are formed from non-specialized 
stem cells.  These specialized, differentiated cells generally perform the work of tissues 
in an organism.  Tumors may develop as a result of incomplete differentiation of these 
stem cells, which may occur as a result of mutations in their DNA, or dedifferentiation of 
fully differentiated cells.   Accumulation of mutations in cells may prevent cells from 
undergoing complete differentiation which could lead to cancer development12,1,15.  
The carcinogenesis process is influenced by environmental and hereditary 
factors16.  Hereditary factors typically range from 5% to 10% of all cancers while 
environmental factors account for 90% to 95% of cancers17.  Environmental factors 
include obesity, poor nutrition, physical inactivity, radiation, tobacco usage, and 
exposure to pollutants from the environment17. 
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Colorectal Cancer and its Risk Factors      
Colorectal cancer is ranked as the third most common cancer in both males and 
females16.  In 2014, approximately 136,830 colorectal cancer cases with 50,310 deaths 
are anticipated to occur in the United States.   Colorectal cancer risk increases with age 
and 90% of colorectal cancer cases are identified in people who are 50 years and older.  
Alcohol intake, chronic smoking, lower intake of fruits and vegetables as well as a diet 
rich in meat (red or processed) are environmental factors that enhance the risk of 
developing colorectal cancer16. 
Tobacco smoking is a major cause of cancer worldwide18.   More than 60 
carcinogens have been confirmed to be present in cigarette smoke19. These include 
aldehydes, volatile organic hydrocarbons, N-nitrosamines, aromatic amines, metals, 
and polycyclic aromatic hydrocarbons (PAHs).  Among these, the major carcinogens in 
human cancers are N-nitrosamines, aromatic amines, and PAHs19.  The relationship 
between tobacco products and cancer development in humans is due to the presence 
of these carcinogens20,21.  Cancer associated with tobacco consumption includes 
bladder, lung, stomach, kidney, colorectal, and pancreatic cancers18.  It has been shown 
that smokers have a greater risk of developing colorectal cancer compared with non-
smokers22.  In addition, the risk of developing colorectal cancer is linked to the number 
of years of cigarette smoking22.  
 Cigarette smoke extract enhances the growth of colorectal tumors by up-
regulating the expression of cyclooxygenase-2 (COX-2) and 5-LOX proteins as well as 
their metabolites prostaglandins E2 (PGE2 ) and leukotriene B4, in colorectal tumors
23.  
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Nicotine, a primary constituent of cigarettes increases cell proliferation in human 
colorectal cancer cell lines24.  These findings indicate that tobacco constituents play a 
critical role in colorectal tumorigenesis. 
Dietary factors have also been associated with colorectal cancer development.  
For example, high intake of fruits (e.g. banana, fruit juice, pear, citrus fruits, and apple) 
and vegetables (e.g. spinach, tomato, carrot, cabbage) are inversely linked to colorectal 
cancer development25.  The intake of fruit fiber is also shown to be inversely linked to 
the risk of developing colorectal cancer26. 
However, a high intake of red (e.g. lamb, beef and pork) and processed meat 
(e.g. corned beef, chicken, ham, sausages, bacon etc.) is reported to be significantly 
linked to enhanced risk of colorectal cancer development27,26.  Animal fat including 
monounsaturated fat and saturated fat is positively linked to the risk of developing 
colorectal cancer26.  In addition, a significant inverse link is observed between 
polyunsaturated fatty acids and colorectal cancer development28.    
The Role of Polyunsaturated Fatty Acid Metabolites and Their Enzymes in Cancer 
Bioactive products such as PGs, HETEs, and HODEs produced through the 
metabolism of arachidonic acid (AA)  and linoleic acid (LA) by LOX and COX enzymes 
are associated with carcinogenesis29,30,31.  
COX enzymes metabolize AA to produce thromboxane A2 (TXA2 ) and PGs (D2 
and E2)32.  LOX enzymes also metabolize AA to produce hydroperoxyeicosatetraenoic 
acids, which are subsequently reduced to form HETEs.  The main LOX enzymes 
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present in humans are 15-LOX, 5-LOX, and 12-LOX which metabolize AA to produce 
15-HETE, 5-HETE, and 12-HETE, respectively33,34.  15-LOX also metabolizes LA to 
produce 13-HODE and 9-HODE34.  Production of LOX and COX metabolites are 
illustrated in Figures 1, 2, and 335,36. 
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Figure 1. The production of TXA2, PGD2, and PGE2 through the metabolism of AA by COX enzymes 
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Figure 2. The production of 15-HETE, 12-HETE, and 5-HETE through the metabolism of AA by LOX 
enzymes 15-LOX-1, 12-LOX, and 5-LOX respectively 
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Figure 3. The production of 13-HODE through the metabolism of LA by 15-LOX-1 enzymes 
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A number of studies indicate that COX and LOX pathways play important roles in 
cancer development37,38.  For instance, COX-2 is highly expressed in various tumors 
including prostate and colorectal tumors39,37,40.  Also, 12-LOX and its metabolite12-
HETE are shown to be highly expressed in colorectal tumors compared with the normal 
colorectal tissue, indicating that over expression of the 12-LOX pathway enhances 
colorectal carcinogenesis41,42,43.  High levels of 12-HETE in colorectal cancer cells 
enhances cell proliferation which is important to colorectal cancer development41,44.  
Hence, inhibiting the production of 12-HETE may slow proliferation in colorectal cancer 
cells.  This was demonstrated when the reduction of 12-HETE production by sulindac (a 
non-steroidal anti-inflammatory drug (NSAID) decreased the colon tumor growth in 
Fischer 344 rats42.  Also, a decrease in 12-HETE production by baicalein (a 12-LOX 
inhibitor) hindered cell proliferation in Caco-2 human colon cancer cells44.  These 
studies indicate that, blocking the 12-LOX pathway is important in preventing colorectal 
cancer development. 
In addition to colorectal cancer cells, 12-LOX is also shown to be highly 
expressed in prostate cancer cells45,46.  This was demonstrated in a study that analyzed 
the expression of 12-LOX in the cancer and normal tissue collected from the prostate of 
122 prostate cancer patients.  Approximately half of prostate cancer patients had high 
levels of 12-LOX in their prostate cancer tissues compared to their corresponding 
normal prostate tissues, suggesting that 12-LOX may contribute to the progression of 
prostate tumors45.   Blocking 12-LOX pathway by its inhibitors (i.e. N-benzyl-N-hydroxy-
5-phenylpentamide (BHPP) and baicalein) was shown to enhance apoptosis, decrease 
cell proliferation and cause cell cycle arrest in prostate cancer cells (DU-145 and 
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PC3)46.  It was observed that BHPP and baicalein inhibited about 50% of DU-145 and 
PC3 cells from proliferating in a concentration dependent manner (5–50 µM).  
Subsequently, inhibition of 12-LOX results in cell cycle arrest as observed by an 
increase in the number of cells in G0/G1 phase, a decreased expression of G1 phase 
proteins (Cdk2/4 and cyclins D1 and D2), a decrease in cell number in S phase and G2-
M phase, and decreased expression of the anti-apoptotic protein, bcl-246.  These results 
indicate that 12-LOX plays an important role in enhancing cell proliferation and 
preventing apoptosis in prostate cancer and hence, blocking this pathway may be 
important in suppressing both prostate and colon cancer development. 12-LOX and its 
metabolite 12-HETE is also expressed in other cancer cell lines such as W256 cells (a 
rat Walker carcinoma cells)31,43.  In the W256 cells, it was observed that treatment with 
the 12-LOX inhibitor, BHPP hindered cell growth31.  These studies suggest that blocking 
the 12-LOX pathway may result in suppressing tumorigenesis in various tissue types.   
5-LOX is also linked to cancer development38,47.  For example, 5-LOX is highly 
expressed in colorectal tumors as compared with normal colorectal tissues48,47.  Higher 
levels of 5-HETE, a 5-LOX metabolite are reported in colorectal cancer cells44,42.  These 
observations suggest that the 5-LOX pathway may also enhance colorectal 
tumorigenesis.  It is observed that the treatment of colorectal cancer cells (Caco-2 and 
LoVo cells) with 5-LOX inhibitors (1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-
α,α-dimethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid (MK 886) and α-pentyl-3-(2-
quinolinylmethoxy)-benzenemethanol (Rev5901)) decrease the proliferation of the cells, 
26 
 
indicating that colorectal carcinogenesis may be suppressed as the 5-LOX pathway is 
blocked44,47. 
In addition to colorectal cancer cells, high levels of 5-HETE are present in the 
prostate cancer cells PC3 and LNCaP38.  The presence of 5-HETE enhances cell 
proliferation in these prostate cancer cells suggesting the key role for 5-HETE in 
prostate cancer development49.  Treatment of PC3 and LNCaP cells with 5-LOX 
inhibitors (MK886 and 2-(12-Hydroxydodecane-5, 10-diynyl)-3, 5, 6-trimethyl-p-
benzoquinone (AA861)) induces apoptosis and inhibits cell growth49,38 indicating that, 
the 5-LOX pathway is essential in prostate cancer progression. 
13-HODE, another metabolite of LOX enzymes is produced when LA is 
metabolize by the15-LOX-1 enzyme50.  Higher levels of 13-HODE are found to be 
present in normal colorectal tissues compared with colorectal cancer tissue51,52, 
suggesting a protective effect of 13-HODE against colorectal cancer.  15-LOX-1, the 
enzyme which metabolizes LA to produce 13-HODE, is reduced in colorectal tumors 
compared with normal colorectal tissues, indicating that loss of 15-LOX-1 expression 
enhances colorectal tumorigenesis52.  
 13-HODE plays a significant role in preventing colorectal cancer progression by 
inducing apoptosis, reducing cell proliferation, and inhibiting the continuation of the cell 
cycle in colorectal cancer cells (RKO and HT-29 cells)52.  These results indicate that 13-
HODE up regulation suppresses colorectal tumorigenesis.  As a result NSAIDs such as 
sulindac, sulindac sulfone, and N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide 
(NS-398) have been found to increase 13-HODE production as well as 15-LOX-1 
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expression in colorectal cancer cell lines (DLD-1, RKO,  and HT-29 cells)53,54.  Apart 
from colorectal cancer cells, the level of 13-HODE production in esophageal, breast, 
and lung cancer cells is also reduced compared with their normal cell 
counterparts55,56,57, suggesting that 13-HODE formation is crucial in suppressing the 
development of these cancers. 
LOX metabolites have been identified as endogenous ligands of peroxisome 
proliferator-activated receptor γ (PPAR γ)58,59.  PPAR γ is a nuclear receptor identified to 
be highly present in adipose tissues and controls adipocyte differentiation60.  PPAR γ is 
also seen to be highly expressed in cancer cells such as colon, breast, bladder and 
prostate cancers61,62,63,64,65.  Ligand activation of PPAR γ causes differentiation, hinders 
cell proliferation, and enhances apoptosis of cancer cells65,61,62.  PPAR γ is activated by 
synthetic ligands such as thiazolidinediones (e.g. rosiglitazone (BRL 49653) and 
troglitazone)61 and endogenous ligands such as 15-HETE, 13-HODE and 9-HODE66,59.  
 In colorectal cancer cells (Moser and HT-29 cells), it is reported that ligand 
activation of PPAR γ by 15-deoxy-delta-12, 14-prostaglandin J2 , BRL49653, and 
troglitazone reduces cell proliferation, enhances cell differentiation, and impedes G1 
cycle progression61,65.   In breast cancer cells (MCF7), ligand activation of PPAR γ by an 
all trans-retinoic acid and troglitazone mixture decreases the tumor volume of MCF7 
cells in mice and enhances apoptosis in MCF7 cells observed by a reduction in bcl-2 
protein expression62.  PPAR γ activation by 15-HETE reduces cell proliferation in 
prostate cancer cells66.  These findings suggest that up regulating endogenous PPAR γ 
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ligands such as 13-HODE could repress the progression of cancers such as colon, 
esophageal, breast, and lung cancer, which have decreased levels of 13-HODE. 
15-HETE, a 15-LOX-1 metabolite is also identified in colorectal cancer 
tissues44,67.   Higher levels of 15-HETE are shown to be present in colorectal tumors 
compared with the normal colorectal tissues42,44.  The presence of 15-HETE in 
colorectal cancer cells (Caco-2 cells) has also been demonstrated to enhance the 
growth of the cells, indicating that high levels of 15-HETE may enhance colorectal 
carcinogenesis44.  
Vitamin E and its Role in Cancer Development 
Vitamin E is a family of compounds that include isoforms of tocopherols and 
tocotrienols.  Tocotrienols and tocopherols have four different isoforms that vary from 
each other by the number and arrangement of methyl groups on the chromanol head.  
These isoforms include alpha, beta, gamma, and delta68.  Both families of compounds 
possess a chromanol head with tocopherol having a phytyl tail and tocotrienols having 
an isoprenoid tail69.  Vitamin E is obtained from nuts, vegetable oil, and grains70.  The 
structures of the different vitamin E isoforms are shown in Figure 471. 
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Vitamin E is recognized by its ability to function as an antioxidant by donating its 
phenolic hydrogen to primarily quench peroxyl radicals, as well as other ROS such as  
hydroxyl radicals etc., and hence prevent these ROS from attacking lipids, proteins, cell 
membranes, and nucleic acids (e.g. DNA)72,73,4,2.   Scavenging of these ROS by vitamin 
E may prevent continual DNA damage which could lead to cancer initiation3,4.  
A number of studies have shown an inverse link between vitamin E and the risk 
of developing cancer.  For example, it has been reported in a study that mice fed 600 
mg of vitamin E (form not specified, but likely all-rac-alpha-tocopheryl acetate) per 
kilogram of diet, the vitamin E group developed low number of colon tumors compared 
to a non-vitamin E-supplemented group74.  It has also been reported that high amounts 
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Figure 4. The structure of tocopherols and tocotrienols. Alpha isoform when R1 and R2 represent CH3 and 
CH3, beta isoform when R1 and R2 represent CH3 and H, gamma isoform when R1 and R2 represent H and 
CH3, delta isoform when R1 and R2 represent H and H 
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of AT in human serum is associated with a reduced risk of developing gastric cancer75.   
A mixture of synthetic vitamin E (all-rac-alpha-tocopheryl acetate) and lycopene (5 
mg/kg body weight each) has also been shown to reduce the growth of prostate tumors 
as well as enhance the  survival of the mice in a PC-346C mouse xenograft model76.   
Alpha-tocopheryl succinate (2-20 µM), a synthetic vitamin E ester has also been 
reported to decrease proliferation and cause cell cycle arrest in prostate cancer cells 
(LNCaP cells).  Cell cycle arrest in LNCaP cells was observed by an increase in the 
number of cells in G1 phase and a decrease in cell number in S and G2 phase.  In this 
same study, a decrease in the expression of cycle proteins such as cdk4, cdk2, cyclin 
D3, cyclin D4, and cyclin E (G1/S proteins) was observed after treating the LNCaP cells 
with alpha-tocopheryl succinate77.  Over expression of the proteins cdk4, cdk2, cyclin, 
D3 cyclin D4, and cyclin E enhances cell proliferation, hence, a decrease in these 
proteins by alpha tocopheryl succinate would impede progression in LNCaP cells.   
These findings suggest that vitamin E esters exhibit anti-cancer properties and may play 
a significant role in suppressing cancer development. 
 Although a majority of studies conducted with vitamin E in relation to cancer 
prevention have been performed with AT or AT derivatives75,76,16,77, GT exhibits better 
anti-cancer activity than AT.  For example, GT is shown to decrease human breast and 
mammary tumors (MDA-MB-231-GFP and 66cl-4-GFP cells) and induce apoptosis in 
mice, while neither AT nor a mixture of AT and GT had any effect on the tumor volume 
nor induced apoptosis in these mice78,79. 
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In colorectal cancer cell lines (HCT-116, HT-29, and CaCo-2 cells), GT 
decreases cell proliferation better than AT80,81.  It was observed that GT significantly 
causes cell death at a concentration as low as 25 µM while AT only results in cell death 
at a concentration of 200 µM compared to the control. GT also induced apoptosis in 
HCT-116 and SW480 cells better than AT81.  GT has also been shown to increase 
PPAR γ expression better than AT in SW480 cells colorectal cancer cells82. 
In the LNCaP and DU-145 cells prostate cancer cells, 25 µM GT was shown to 
effectively reduce cell proliferation compared to 25 µM AT.  In this study, GT causes 
more than a 70% decrease in cell proliferation while AT causes about a 50% reduction 
in proliferation80.  GT decreases the cell proliferation in PC-3 cells as well as the 
expression of cyclin D1, D3, and E (G1 check point proteins) in prostate cancer cell lines 
PC-3, LNCaP, and DU-14580,83.  Over expression of the proteins cyclin D1, D3, and E 
mediates cell proliferation.  Hence a decrease in these proteins by GT would impede 
the progression of the cell cycle at G1 phase and hence slow proliferation of the prostate 
cancer cells80,83.   
These findings suggest that GT regulates pathways in cancer cells such as cell 
proliferation, cell cycle, and apoptosis in order to suppress cancer progression.  These 
findings, also demonstrate that GT is more potent than AT in regulating these pathways 
(i.e. cell proliferation, cell cycle and apoptosis) to prevent cancer development. 
GT3, an isoform of vitamin E containing an isoprenoid tail, has demonstrated 
potent anti-cancer potential.  For example, in MCF-7 and MDA-MB 231 breast cancer 
cells both α-tocotrienol (AT3) and GT3 hindered proliferation of the cells in a 
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concentration dependent manner (10-40 µM)84. However, the proliferation of the cells in 
GT3-treated sample was less than the proliferation in the AT3-treated cells suggesting 
that GT3 is a more potent anti-cancer agent than AT3.  In addition, GT3 decreases G1 
phase check proteins such as CdK4 and cyclins D1/D3 in MCF-7 cells which indicates 
that GT3 can cause cell cycle arrest at G1 phase
84. 
In other cancer tissue types such as the human cervical cancer HeLa cell line,  
both AT3 and GT3 decrease cell proliferation with GT3 showing a greater inhibitory 
effect than AT385.  Both AT3 and GT3 also impede the progression of the cell cycle in 
HeLa cells as observed by an increase in the number of cells in G0/G1 phase and 
decrease in cell number in the S phase85.  
Finally, in the RKO colorectal cancer cell line, the tocotrienol-rich fraction 
consisting of a mixture of AT, beta tocopherol (BT), and GT isoforms hinders cell 
growth, induces apoptosis, causes cell cycle arrest at G1, and increases the expression 
of p53 proteins in the RKO cells86.  These studies indicate that tocotrienols also regulate 
various pathways such as cell cycle, cell proliferation, and apoptosis in cancer cells to 
prevent cancer progression.   In addition, these studies suggest that GT3 exhibits 
greater anti-cancer activity than AT3.  
Based on these observations, vitamin E (tocopherols and tocotrienols) can be 
said to exhibit anti-tumor activity by regulating various pathways in cancer cells such as 
cell proliferation and apoptosis.  These studies also suggest that the development of 
colorectal cancer is enhanced by low production of 13-HODE and high production of 15-
HETE, 12-HETE, and 5-HETE.  Therefore, we hypothesize that vitamin E (tocopherols 
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and tocotrienols) can increase the production of 13-HODE and decrease the production 
of 15-HETE, 12-HETE, and 5-HETE in colorectal cancer cells. 
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CHAPTER 2 
METHODS 
Cell Culture 
Human colon cancer cells (HCT-116 cell line) were cultured in McCoy’s 5A 
media which is enriched with 10% fetal bovine serum (FBS) and 50 IU 
penicillin/streptomycin in an environment with 5% carbon dioxide at 37 ºC83. 
Determination of Concentrations of AT, GT, GT3, and a Mixture of Alpha (5%) and 
Gamma Tocopherol (95%)(ATGT)  
The concentrations of AT, GT, GT3, and ATGT were determined using an HP-
8542A diode array spectrophotometer. The wavelength of maximum (max) absorbance 
(λmax) for GT, GT3, and ATGT is 298 nm and that of AT is 292 nm. The molar 
absorptivity (ε) for GT and ATGT is 3810, AT is 3270, and GT3 is 4230.  The Beer-
Lambert Law was used to calculate the concentration of the vitamin E isoforms using 
the absorbance and the ε at the appropriate λmax
83
.   
Sample Preparation for Liquid Chromatography Mass spectrometry Analysis 
(LC/MS/MS) 
Treatment of Cells.  HCT-116 cells were seeded at a concentration of 2.5 x 106 in 
a T-75 mL flask or 10 mm round dishes for 24 hours before treatment.  The cells were 
then treated with 5 µM of AT, GT, GT3, and ATGT for 24 hours. The untreated cells 
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(vehicle) were also prepared with a volume of ethanol corresponding to the volume of 
vitamin E added for 24 hours83. 
Extraction of Fatty Acid Metabolites from Cells.  After 24 hours of treatment, the 
media was removed from the cells and stored in a -80 ºC freezer for a period of no 
longer than 1 week before the analysis was performed.  The cells were harvested with 5 
mL of trypsin (0.25%) with balanced salts (Hyclone SH30042.02) and collected by 
centrifugation.  The cell pellet was washed with 5 mL of phosphate buffered saline 
(PBS), and collected by centrifugation. The cells were re-suspended in 500 µL of PBS 
with 1 mM calcium chloride solution and incubated at 37ºC for 2 minutes87.  As 
previously described, an aliquot 2.5 µL of calcium ionophore A23187 (1 mM) was added 
to the mixture, followed by addition of 100 µM of AA87.  The ionophore in this reaction 
will demonstrate the activity of the LOX pathway, and in the presence of additional 
substrate (AA) it will show that the LOX enzyme is still active upon production of 
metabolite. The reaction mixture was incubated at 37ºC for 10 minute under minimal 
light87.  After incubation, the cells were then collected by centrifugation.  Using an 
enzyme-linked immunosorbent assay (ELISA) assay (Enzo Life Sciences, Farmingdale, 
NY) according to the manufacturers’ protocol, the cell pellets were then washed with 1 
mL of ice cold PBS, and recollected by centrifugation.  The cells were lysed with ice 
cold lysis buffer (200 µL) and acidified to pH 3.5-4.0 with 0.2 N HCl.  The fatty acid 
metabolites were extracted from the reaction mixture three times using a 3-fold excess 
of ethyl acetate.  The upper layer (organic phase) were collected into a fresh tube and 
dried under a stream of nitrogen gas. The dried samples were stored in a -80 ºC freezer 
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no longer than one week before analysis was performed. The dried samples were 
dissolved in 100 µL of methanol and filtered for LC/MS/MS analysis immediately before 
analysis.  
Extraction of Fatty Acid Metabolites from Media.  A solid phase extraction (Sep-
Pak) cartridge was conditioned with methanol and equilibrated with water under gravity, 
then loaded with 3 mL of sample.  The column was then washed with 3 mL of the 
following solvents, water, 15% ethanol, and hexane.  Following the washes, 1 mL of 
methanol was added to the cartridge and centrifuged for 10 minutes to collect the 
analytes.  The eluent containing the analytes was dried under nitrogen gas and stored 
in a -80ºC freezer no longer for a period of one week before analysis. Just prior to the 
analysis, the dried sample was dissolved in 100 µL of methanol and filtered for 
LC/MS/MS analysis88. 
Analysis of Fatty Acid Metabolites Using Gradient LC/MS/MS 
Separation and detection of metabolites was achieved using the Shimadzu IT-
TOF (ion trap-time of flight) LC/MS/MS with an ultrasphere C18 4.6 mm * 250 mm 
column (5µm, Beckman)89.  Mobile phase A contains 30% acetonitrile/70% 0.1% formic 
acid in water and mobile phase B contains of 0.1% formic acid in acetonitrile.  Mobile 
phase A and B were delivered at a flow rate of 0.5 mL/min with the following gradient: 
75-90% B in 10 min: 90% B in 2 min: 75 % B in 5 min.  The volume of sample injected 
was 10 µL and the column temperature was kept at 40ºC.  The metabolites were 
detected with the Shimadzu IT-TOF mass spectrometer (Columbia, MD), which is run in 
electrospray negative mode with a source temperature of 200ºC. The metabolites were 
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identified based on their m/z ratios and their retention times.  The m/z of HETEs (12-
HETE, 15-HETE, and 5-HETE) was 319.22 and 13-HODE was 295.2289.  All samples 
and external standards (12-HETE, 15-HETE, and 5-HETE prepared standards) were 
analyzed in duplicate. 
Sample Preparation for ELISA Analysis 
Treatment of Cells.  HCT-116 cells were cultured to about 50-75% confluence.  
The cells were then treated with 5 µM of GT, AT, ATGT, or GT3 for 24 hours.  The 
untreated cell (vehicle) was also prepared for 24 hours. 
Extraction of Fatty Acid Metabolites.  The treated cells were harvested with 5 mL 
of trypsin (0.25%) with balanced salts (Hyclone SH30042.02) and collected by 
centrifugation.  The resulting cell pellets were washed in 5 mL of PBS.  The cells were 
counted with a hemocytometer and a total of 10 million cells collected by centrifugation 
and were resuspended in 500 µL of PBS with 1 mM calcium chloride solution and 
incubated at 37 ºC for 2 minutes87.  An aliquot of 2.5 µL of calcium ionophore A23187 (1 
mM) was added to the mixture, followed by addition of 100 µM of AA87.  The reaction 
mixture was incubated at 37 ºC for 10 minutes at minimum light87.  After incubation, cells 
were collected by centrifugation.  Using an ELISA assay (Enzo Life Sciences, 
Farmingdale, NY) according to the manufacturers’ protocol, cell pellets were then 
washed with 5 mL of ice cold PBS, and recollected by centrifugation.  The cells were 
lysed with 200 µL of ice cold lysis buffer and the lysate was acidified to pH 3.5-4.0 with 
0.2 N HCl.  The fatty acid metabolites were extracted from the reaction mixture three 
times using 3-fold excess of saturated ethyl acetate.  The upper layer (organic phase) 
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were collected into a fresh tube and dried under nitrogen gas.  The dried samples were 
stored in -80 ºC freezer for a period of no longer than one week before prepared for 
analysis by dissolving them in 44 µL of ethanol and 176 µL of assay buffer.  
Analysis of Fatty Acid Metabolites Using ELISA  
The amount of 13-HODE in HCT-116 cells were analyzed using an ELISA assay 
(Enzo Life Sciences, Farmingdale, NY) according to the manufacturers’ protocol.  The 
optical density was read at 405 nm with ultraviolet-visible (UV-VIS) spectrophotometer 
plate reader (Molecular Devices, Spectra Max Plus 384).  
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CHAPTER 3 
RESULTS 
LC/MS/MS Chromatogram for Fatty Acid Metabolites in HCT-116 Cells 
The amount (nmoles) of 12-HETE, 5-HETE, 15-HETE, and 13-HODE in the cells 
and the media of HCT-116 cell line were determined from the concentrations obtained 
from peak areas using the Shimadzu IT-TOF (ion trap-time of flight) LC/MS/MS.  The 
concentration of 12-HETE, 5-HETE, 15-HETE, and 13-HODE corresponding to each 
peak was determined from a calibration graph prepared from a series of standards (0.05 
to 4.5 µg/mL).  Stock solutions (100 µg/mL) of 12-HETE, 5-HETE, 15-HETE, and 13-
HODE standards were used to prepare series of standards (0.05 to 4.5 µg/mL) for the 
calibration graph.  A chromatogram showing the separation of these fatty acid 
metabolites in HCT-116 cells is shown in Figure 5.  The intensities of the peaks are 
measured by the mass spectrometer based on their ion masses to charge ratio (m/z).  
The detection of these metabolites is based on their retention time and mass to 
charge ratio (m/z).  The m/z of HETEs (12-HETE, 15-HETE, and 5-HETE) is 319.22 and 
13-HODE is 295.22.  The retention times of 13-HODE, 15-HETE, 12-HETE and 5-HETE 
are 8.135, 8.22, 8.851 and 9.321 min, respectively.  Since the retention time of 13-
HODE (8.135 min) and 15-HETE (8.22 min) are very close, their identification is made 
easier by the mass spectrometry using their molecular weight differences.  Mass 
spectrometry was chosen as the method of analysis because the concentrations of 
these metabolites in the HCT-116 cells are low, ranging from 0.05 - 4.5 µg/mL and 
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require a more sensitive instrument for detection.  Since the mass spectrometry is 
highly sensitive compared to optical methods such as a UV-VIS spectrophotometry90, it 
allows the injection of very low sample volume (10 µL)  preventing the broadening and 
overlapping of peaks. 
 
 
 
 
Figure 5.  The chromatogram of fatty acid metabolites (13-HODE, 15-HETE, 12-HETE, and 5-HETE) in HCT-
116 cells obtained by the Shimadzu LC/MS/MS. This chromatogram represents a 10 µL injection of 4.5 µg/mL 
solution of 15-HETE, 12-HETE, 5-HETE, and 13-HODE. The 4.5 µg/mL standard solutions were prepared 
from a 100 µg/mL stock solution in ethanol. These metabolites were separated using mobile phase A (30% 
acetonitrile/70% 0.1% formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile).  Mobile 
phase A and B were delivered at a flow rate of 0.5 mL/min with the following gradient: 75-90% B in 10 min: 
90% B in 2 min: 75 % B in 5 min   
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Amounts of 13-HODE, 15-HETE, 12-HETE, and 5-HETE, Secreted into the Media of 
HCT-116 Cells Following Treatment of HCT-116 Cells with GT, AT, ATGT, and GT3. 
The metabolites 13-HODE, 15-HETE, 12-HETE, and 5-HETE accumulate in the 
cells and then are secreted out of the cells into the extracellular space or the media.  
Hence, the amounts of the metabolites (13-HODE, 15-HETE, 12-HETE, and 5-HETE) in 
the media of HCT-116 cells were analyzed using the LC/MS/MS method and used as a 
measure of metabolite production.  The formation of the metabolites and secretion into 
the media occur under normal physiological conditions. 
The Amount of 13-HODE Secreted into the Media of HCT-116 Cells is Increased by GT 
or ATGT but not GT3 nor AT under Physiological Conditions. 
13-HODE has been shown to inhibit cell proliferation and induce apoptosis in 
colorectal cancer cells52, but the level of 13-HODE in colorectal cancer cells is low 
compared to normal colorectal cells51.  By increasing the level of 13-HODE, a decrease 
in cell proliferation in colorectal cancer cells is possible52.  Hence, we decided to 
investigate whether GT, ATGT, AT, and GT3 can increase the amount of 13-HODE 
secreted into the media of HCT-116 cells.   
The treatment of HCT-116 cells with 5 µM GT significantly increases the amount 
of 13-HODE as compared with the vehicle in the media of HCT-116 cells (Figure 6; p = 
0.038).  Under physiological conditions, the amount of 13-HODE secreted into the 
media of the GT treated samples is more than a five-fold increase over the vehicle 
treated samples. 
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Figure 6.  The effect of ATGT on the amount of 13-HODE secreted into the media of HCT-116 cells as 
analyzed by LC/MS/MS.  HCT-116 cells were treated with and without 5 µM ATGT for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 13-HODE in the media 
was determined by stand curve analysis.  The amount of 13-HODE in the media of HCT-116 cells treated 
with ATGT demonstrate a significant increase over the vehicle-treated cells (n =7; p = 0.045). Statistical 
differences were determined by paired t-test.  p values < 0.05 were determined statistically significant.     
p values are obtained at 95% confidence level.  Error bars are representative of SEM of sample. 
 
Some studies have shown that the inclusion of AT with GT decreases the ability 
of GT to inhibit cell proliferation and induce apoptosis in cancer cells78.  Other studies 
demonstrate that AT is less effective at reducing cell proliferation and enhancing 
apoptosis in cancer cells78,79,80,81, therefore we investigated the effect of ATGT mixture 
on the production of fatty acid metabolites (12-HETE, 5-HETE, 15-HETE, and 13-
HODE).    The treatment of HCT-116 cells with 5 µM ATGT mixture (95% GT and 5% 
AT) under physiological conditions, also increases the amount of 13-HODE significantly 
as compared with the vehicle in the media of HCT-116 cells (p = 0.045) as shown in 
Figure 7.  While the amount of 13-HODE secreted into the media in the ATGT treated 
samples was less than a two- fold increase over the vehicle, the 5 µM GT treatment of 
HCT-116 cells increases the amount of 13-HODE greater than five-fold over the vehicle 
in the media (Figure 6).  The decrease in amount of 13-HODE in the ATGT treated 
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samples compared with the GT treated samples may be due to the presence of the 5% 
AT.  This was confirmed when the addition of 5 µM pure AT to HCT-116 cells did not 
significantly increase the amount of 13-HODE in the media of HCT-116 cells after 
treatment with 5 µM pure AT as compared with the vehicle (Figure 8; p < 0.068), 
suggesting that AT does not  increase the amount of 13-HODE in the media of HCT-116 
cells and that the addition of AT decreases the ability of GT to increase the amount of 
13-HODE in the media of HCT-116 cells. 
 
Figure 7.  The effect of ATGT on the amount of 13-HODE secreted into the media of HCT-116 cells as 
analyzed by LC/MS/MS.  HCT-116 cells were treated with and without 5 µM ATGT for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 13-HODE in the media 
was determined by stand curve analysis.  The amount of 13-HODE in the media of HCT-116 cells treated 
with ATGT demonstrate a significant increase over the vehicle-treated cells (n =7; p = 0.045). Statistical 
differences were determined by paired t-test.  p values < 0.05 were determined statistically significant.   p 
values are obtained at 95% confidence level.  Error bars are representative of SEM of sample. 
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Figure 8. The effect of AT on the amount of 13-HODE secreted into the media of HCT-116 cells as 
analyzed by LC/MS/MS.  HCT-116 cells were treated with and without 5 µM AT for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 13-HODE in the media 
was determined by stand curve analysis.  The amount of 13-HODE in the media of HCT-116 cells treated 
with AT cells demonstrated no statistical difference between the AT treated sample compared with the 
vehicle treated sample (n = 8; p = 0.068). Statistical differences were determined by paired t-test.  p 
values < 0.05 were determined to be statistically significant.   p values are obtained at 95% confidence 
level.  Error bars are representative of SEM of sample 
 
While both GT and ATGT significantly increase the amount of 13-HODE in the 
media of HCT-116 cells, the amount of 13-HODE secreted into the media of HCT-116 
cells did not significantly change following treatment with 5 µM GT3 compared to the 
vehicle (Figure 9; p = 0.37).  These data (Figures 8 and 9) suggest that neither GT3 nor 
AT may be the best isoform of vitamin E to induce an up-regulation of 13-HODE in the 
media of HCT-116 cells.  Other isoforms of vitamin E such as GT, as well as the 
combination of AT and GT (ATGT) should be considered when an increase in 13-HODE 
production in HCT-116 cells is to be achieved. 
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Figure 9.  The effect of GT3 on the amount of 13-HODE secreted into the media of HCT-116 cells 
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT3 for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 13-HODE in the media 
was determined by stand curve analysis. The amount of 13-HODE in the media of HCT-116 cells treated 
with GT3 demonstrated no statistical difference between the GT3 treated sample compared with the 
vehicle treated sample (n =7; p = 0.37). Statistical differences were determined by paired t-test.  p values 
< 0.05 were determined to be  statistically significant.   p values are obtained at 95% confidence level.  
Error bars are representative of SEM of sample. 
 
GT, ATGT, AT or GT3 did not Regulate the Amount of 15-HETE in the Media of HCT-
116 Cells under Physiological Conditions. 
15-HETE, a 15-LOX-1 metabolite, has been shown to be high in colorectal 
cancer cells44.   Higher levels of 15-HETE have been observed to enhance the growth 
of colorectal cancer cells44,42.  We, therefore, investigated whether vitamin E isoforms, 
GT, GT3, AT, and ATGT can cause a reduction in the amount of 15-HETE in the media 
of HCT-116 cells. The amount of 15-HETE in the media of HCT-116 cells did not show 
a statistical difference after treatment with 5 µM GT under physiological conditions as 
compared with the vehicle (Figure10; p = 0.36).  Further, the amount of 15-HETE in the 
media of HCT-116 cells following treatment with 5 µM ATGT under physiological 
conditions did not show a statistical difference as compared with the vehicle (Figure 11; 
p = 0.25). In addition, the amount of 15-HETE in the media of HCT-116 cells following 
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treatment with 5 µM AT did not show a statistical difference after treatment as compared 
with the vehicle (Figure 12; p = 0.49).  Alongside GT (Figure 10), ATGT (Figure 11), and 
AT (Figure 12), the amount of 15-HETE in the media of HCT-116 cells following 
treatment with 5 µM GT3 did not show a statistical difference after treatment with 5 µM 
GT3 as compared to the vehicle (Figure13; p = 0.47).  These data demonstrate that the 
production of 15-HETE under physiological conditions is not regulated by any of the 
vitamin E isoforms tested (GT, AT, GT3) nor the ATGT mixture. 
 
 
 
Figure 10.  The effect of GT on the amount of 15-HETEsecreted into the media of HCT-116 cells as 
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.  The amount of 15-HETE in the media 
was determined by stand curve analysis. The amount of 15-HETE in the media of HCT-116 cells treated 
with GT demonstrated no statistical difference between the GT treated sample compared with the vehicle 
treated sample (n =10; p = 0.36). Statistical differences were determined by paired t-test.  p values < 0.05 
were determined to be statistically significant.   p values are obtained at 95% confidence level.  Error bars 
are representative of SEM of sample. 
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Figure 11.  The effect of ATGT on the amount of 15-HETE secreted into the media of HCT-116 cells as 
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM ATGT for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 15-HETE in the media 
was determined by stand curve analysis. The amount of 15-HETE in the media of HCT-116 cells treated 
with ATGT demonstrated no statistical difference between the ATGT-treated sample compared with the 
vehicle-treated sample (n = 8; p = 0.25). Statistical differences were determined by paired t-test.  p values 
< 0.05 were determined to be statistically significant.   p values were obtained at 95% confidence level.  
Error bars are representative of SEM of sample. 
 
 
Figure 12.  The effect of AT on the amount of 15-HETE secreted into the media of HCT-116 cells as 
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM AT for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 15-HETE in the 
media was determined by stand curve analysis. The amount of 15-HETE in the media of HCT-116 cells 
treated with AT demonstrated no statistical difference between the AT-treated sample compared with 
the vehicle-treated sample (n =8; p = 0.49). Statistical differences were determined by paired t-test.   p 
values < 0.05 were determined to be statistically significant. p values are obtained at 95% confidence 
level.  Error bars are representative of SEM of sample. 
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Figure 13. The effect of GT3 on the amount of 15-HETE secreted into the media of HCT-116 cells as 
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT3 for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 15-HETE in the media 
was determined by stand curve analysis. The amount of 15-HETE in the media of HCT-116 cells treated 
with GT3 demonstrated no statistical difference between the GT3-treated sample compared with the 
vehicle-treated sample (n =8; p = 0.47). Statistical differences were determined by paired t-test.  p values 
< 0.05 were determined statistically significant. p values are obtained at 95% confidence level.  Error bars 
are representative of SEM of sample. 
 
GT, but not GT3, AT, or ATGT Treatments Result in the Reduction of the 12-LOX 
Metabolite, 12-HETE in HCT-116 Cells under Physiological Conditions.  
12-HETE is produced through the metabolism of AA by the 12-LOX enzyme.  12-
HETE is found to play a role in the survival of cancer cells43,31.  Higher levels of 12-
HETE is found to be present in the colorectal cancer cells compared to the normal 
colorectal cells41,44.  This high level of 12-HETE is shown to enhance cell proliferation in 
cancer cells including colorectal and prostate cancers44,41,16,46.   Reduction in the level of 
12-HETE by its inhibitors (i.e. flavonoid, baicalein, and cinnamyl-3, 4-dihydroxy-a-
cyanocinnamide), decreased cell proliferation in cancer cells43,31.   We have, therefore, 
investigated whether the amount of 12-HETE secreted into the media of HCT-116 cells 
can be reduced by treatment with vitamin E isoforms GT, GT3, AT, and ATGT.  
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The amount of 12-HETE secreted into the media under physiological conditions 
was significantly decreased following treatment of HCT-116 cells with 5 µM GT as 
compared to the vehicle (Figure 14; p = 0.0014).  However, the amount of 12-HETE 
secreted into the media of HCT-116 cells after treatment of the cells with 5 µM ATGT 
under physiological conditions did not show a statistical difference as compared with the 
vehicle (Figure 15; p = 0.30).  In addition, the amount of 12-HETE secreted into the 
media following treatment of HCT-116 cells with 5 µM AT under physiological conditions 
did not show statistical difference compared with the vehicle (Figure 16; p = 0.45). 
Treatment of HCT-116 cells with GT3 did not show a statistical significance difference in 
the amount of 12-HETE secreted into the media compared with the vehicle (Figure 17; p 
= 0.29).  These data show that the amount of 12-HETE produced into the media of 
HCT-116 is reduced only by GT treatment.  
 
Figure 14.  The effect of GT on the amount of 12-HETE secreted into the media of HCT-116 cells as 
analyzed by LC/MS/MS.  HCT-116 cells were treated with and without 5 µM GT for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 12-HETE in the media 
was determined by stand curve analysis. The amount of 12-HETE in the media of HCT-116 cells treated 
with GT demonstrates a significant decrease over the vehicle-treated cells (n =7; p = 0.0014). Statistical 
differences were determined by paired t-test.  p values < 0.05 were determined to be statistically 
significant.  p values were obtained at 95% confidence level.  Error bars are representative of SEM of 
sample. 
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Figure 15.  The effect of ATGT on the amount of 12-HETE secreted into the media of HCT-116 cells as 
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM ATGT for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 12-HETE in the media 
was determined by stand curve analysis. The amount of 12-HETE in the media of HCT-116 cells treated 
with ATGT demonstrated no statistical difference between the ATGT treated sample compared with the 
vehicle treated sample (n =7; p = 0.30). Statistical differences were determined by paired t-test.  p values 
< 0.05 were determined to be statistically significant.  p values were obtained at 95% confidence level.  
Error bars are representative of SEM of sample. 
 
 Figure 16.  The effect of AT on the amount of 12-HETE secreted into the media of HCT-116 cells as 
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM AT for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 12-HETE in the media 
was determined by stand curve analysis. The amount of 12-HETE in the media of HCT-116 cells treated 
with AT demonstrated no statistical difference between the AT treated sample compared with the vehicle 
treated sample (n =8; p = 0.45). Statistical differences were determined by paired t-test.  p values < 0.05 
were determined to be statistically significant.  p values were obtained at 95% confidence level.  Error 
bars are representative of SEM of sample. 
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Figure 17.  The effect of GT3 on the amount of 12-HETE secreted into the media of HCT-116 cells 
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT3 for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 12-HETE in the media 
was determined by stand curve analysis. The amount of 12-HETE in the media of HCT-116 cells treated 
with GT3 demonstrated no statistical difference between the GT3 treated sample compared with the 
vehicle treated sample (n =8; p = 0.29). Statistical differences were determined by paired t-test.  p values 
< 0.05 were determined to be statistically significant.  p values were obtained at 95% confidence level.  
Error bars are representative of SEM of sample. 
 
The Amount of 5-HETE Secreted into the Media of HCT-116 Cells was not Affected by 
GT, AT, ATGT, or GT3 under Physiological Conditions. 
5-LOX, the enzyme which metabolizes AA to produce 5-HETE has been shown 
to be highly expressed in colorectal cancer cells47.   High levels of 5-LOX enzyme in 
colorectal cancer cells is linked to increased tumor size and growth48.   Addition of 5-
LOX inhibitors to colorectal cancer cells decreases cell proliferation47.   We therefore 
chose to investigate whether the addition of vitamin E isoforms, GT, AT, GT3, and 
ATGT mixture can decrease the amount of 5-HETE (5-LOX metabolite) secreted into 
the media of HCT-116 cells.  
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The amount of 5-HETE secreted into the media did not show any significant 
change after treatment of HCT-116 cells under physiological conditions with 5 µM GT as 
compare with the vehicle (Figure 18; p = 0.49).  Further, the amount of 5-HETE 
secreted into the media following treatment of HCT-116 cells with 5 µM ATGT under 
physiological conditions did not show a statistically significant difference compared with 
the vehicle (Figure 19; p = 0.24).  Neither did the amount of 5-HETE secreted into the 
media following treatment of HCT-116 cells under physiological conditions with 5 µM AT 
show a statistically significant difference as compared with the vehicle Figure 20; p = 
0.072. The amount of 5-HETE in the media following treatment of HCT-116 cells under 
physiological conditions with 5 µM GT3 did not show a significance difference as 
compared with the vehicle (Figure 21; p = 0.24).  These data suggest that treatment of 
HCT-116 cells with vitamin E isoforms GT, AT, ATGT mixture as well as GT3, did not 
reduce the amount of 5-HETE secreted into the media. 
 
Figure 18.  The effect of GT on the amount of 5-HETE secreted into the media of HCT-116 cells as 
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 5-HETE in the media 
was determined by stand curve analysis. The amount of 5-HETE in the media of HCT-116 cells treated 
with GT demonstrated no statistical difference between the GT-treated sample compared with the 
vehicle-treated (n =11; p = 0.49). Statistical differences were determined by paired t-test.  p values < 0.05 
were determined to be statistically significant. p values were obtained at 95% confidence level.  Error bars 
are representative of SEM of sample. 
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 Figure 19.  The effect of ATGT on the amount of 5-HETE secreted into the media of HCT-116 cells 
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM ATGT for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 5-HETE in the media 
was determined by stand curve analysis. The amount of 5-HETE in the media of HCT-116 cells treated 
with ATGT demonstrated no statistical difference between the ATGT treated sample compared with the 
vehicle treated sample (n =9; p = 0.24). Statistical differences were determined by paired t-test.  p values 
< 0.05 were determined to be statistically significant. p values were obtained at 95% confidence level.  
Error bars are representative of SEM of sample. 
 
 
Figure 20.  The effect of AT on the amount of 5-HETE secreted into the media of HCT-116 cells as 
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM AT for 24 hours.  The lipid 
content was isolated from the media and analyzed by LC/MS/MS.   The amount of 5-HETE in the media 
was determined by stand curve analysis. The amount of 5-HETE in the media of HCT-116 cells treated 
with AT demonstrated no statistical difference between the AT treated sample compared with the vehicle 
treated sample (n =8; p = 0.072). Statistical differences were determined by paired t-test.  p values < 0.05 
were determined to be statistically significant.  p values were obtained at 95% confidence level.  Error 
bars are representative of SEM of sample. 
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Figure 21.  The effect of GT3 on the amount of 5-HETE secreted into the media of HCT-116 cells 
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT3 for 24 hours.  The lipid 
extract was isolated from the media and analyzed by LC/MS/MS.  The amount of 5-HETE in the media 
was determined by stand curve analysis. The amount of 5-HETE in the media of HCT-116 cells treated 
with GT3 demonstrated no statistical difference between the GT3 treated sample compared with the 
vehicle treated sample (n =9; p = 0.24). Statistical differences were determined by paired t-test.  p values 
< 0.05 were determined to be statistically significant.  p values were obtained at 95% confidence level.  
Error bars are representative of SEM of sample. 
 
The Amount of 13-HODE, 15-HETE, 12-HETE, and 5-HETE Produced in HCT-116 
Cells Following Treatment with GT, AT, ATGT, or GT3 and then Activation of the 
Lipoxygenase Pathway with Calcium Ionophore A23187 and Addition of Arachidonic 
Acid. 
The amount of polyunsaturated fatty acid metabolites, 13-HODE, 15-HETE, 12-
HETE, and 5-HETE were also measured in HCT-116 cells following treatment of HCT-
116 cells with vitamin E isoforms, GT, AT, ATGT, and AT and activation of the LOX 
pathway with the calcium ionophore A23187 and addition of exogenous AA.   If the 
corresponding LOX enzyme was still active after the treatment under physiological 
conditions, the exogenous AA that was added to the cells provides enough substrate to 
be used by the LOX enzymes for the production of 5-HETE, 15-HETE, and 12-HETE in 
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HCT-116 cells.  If the enzyme is inactivated following the secretion of the metabolites 
into the media, additional HETE metabolites will not be produced by the cells.   
Under LOX Activation Conditions, GT3, but not GT, ATGT, or AT Reduce the 
Production of 13-HODE in HCT-116 Cells.  
To obtain a concentration range of 13-HODE in the cells for standard preparation 
and to ensure that the extraction method was valid, the amount of 13-HODE in HCT-
116 cells was initially measured using ELISA method.  This was carried out by 
preparing 13-HODE standards and a calibration graph.  Using the ELISA method, 
amount of 13-HODE in HCT-116 cells following treatment with 5 µM GT after 24 hours 
did not show a statistically significant difference as compared to the vehicle (Figure 22; 
p = 0.096).  Using LC/MS/MS, the amount of 13-HODE produced in HCT-116 cells 
following treatment with 5 µM GT did not show statistical difference as compared with 
the vehicle (Figure 23; p = 0.39).    
 
Figure 22.  The effect of GT on the amount of 13-HODE in HCT-116 cells using the ELISA method.   
HCT-116 cells were treated with 5 M GT for 24 hours.  The lipid content was isolated from HCT-116 
cells following treatment with GT.  Activation of cells with the calcium ionophore A23187 and addition of 
exogenous AA was carried out and the lipids were analyzed by the ELISA method.  The amount of 13-
HODE was determined by stand curve analysis.  The amount of 13-HODE in HCT-116 cells shows no 
statistical difference between the vehicle-treated and the GT-treated sample (n=7; p = 0.096).  Statistical 
differences were determined by paired t-test.   p values < 0.05 were determined statistically significant.  
Error bars are representative of SEM of sample 
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Figure 23. The effect of GT on the amount of 13-HODE in HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM GT for 24 hours.  The lipid content was isolated from 
HCT-116 cells following treatment with GT.  Activation of cells with the calcium ionophore A23187 and 
addition of exogenous AA was carried out and the lipids were analyzed by LC/MS/MS.   The amount of 
13-HODE in HCT-116 cells was determined by stand curve analysis. The amount of 13-HODE in HCT-
116 cells treated with GT demonstrated no statistical difference between the GT- treated sample 
compared with the vehicle-treated sample (n =11; p = 0.39).   Statistical differences were determined by 
paired t-test.  p values < 0.05 were determined statistically significant.   p values were obtained at 95% 
confidence level.  Error bars are representative of SEM of sample. 
 
Treatment of HCT-116 cells with 5 µM ATGT and 5 µM AT did not show 
statistical differences as compared with the vehicle (Figures 24 and 25) with p values of 
0.14 and 0.16, respectively. These data suggest that, after secretion of 13-HODE into 
the media, there is less substrate (linoleic acid) for the 15-LOX-1 to act upon or the 15-
LOX-1 enzyme has been inactivated following the treatment with GT or ATGT  (Figures 
23, 24, and 25). 
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Figure 24.  The effect of ATGT on the amount of 13-HODE of HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM ATGT for 24 hours.  The lipid content was isolated 
from the HCT-116 cells following treatment with ATGT. Activation of cells with the calcium ionophore 
A23187 and the addition of exogenous AA were carried out, and the lipids were analyzed by LC/MS/MS.   
The amount of 13-HODE in the HCT-116 cells was determined by stand curve analysis. The amount of 
13-HODE in HCT-116 cells shows no statistical difference between the ATGT-treated sample and the 
vehicle-treated sample treated sample (n =9; p = 0.14). Statistical differences were determined by paired 
t-test.  p values < 0.05 were determined statistically significant.  p values are obtained at 95% confidence 
level.  Error bars are representative of SEM of sample. 
 
 
Figure 25.  The effect of AT on the amount of 13-HODE of HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM AT for 24 hours.  The lipid content was isolated from 
the HCT-116 cells following treatment with AT. Activation of cells with the calcium ionophore A23187 and 
the addition of exogenous AA were carried out, and the lipids were analyzed by LC/MS/MS.   The amount 
of 13-HODE in the HCT-116 cells was determined by stand curve analysis. The amount of 13-HODE in 
HCT-116 cells shows no statistical difference between the AT-treated sample and the vehicle-treated 
sample (n =8; p = 0.16). Statistical differences were determined by paired t-test.  p values < 0.05 were 
determined statistically significant.  p values are obtained at 95% confidence level.  Error bars are 
representative of SEM of sample. 
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While the treatment of the tocopherols showed no significant increase in 13-
HODE production, treatment of HCT-116 cells with GT3 significantly decreased the 
production of 13-HODE as compared with the vehicle (Figure 26; p = 0.0092).  This 
decrease is likely due to the decrease in the limited substrate availability (linoleic acid), 
if GT3 were decreasing the activity of the 15-LOX-1 enzyme there would be a significant 
decrease in the production of 15-HETE in the presence of GT3, but that does not 
happen (Figure 31).  The decrease in the amount of 13-HODE in HCT-116 cells after 
treatment with 5 µM GT3 was also observed during the preliminary analysis with ELISA 
method (Figure 27). 
 
Figure 26.  The effect of GT3 on the amount of 13-HODE of HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM GT3 for 24 hours.  The lipid content was isolated from 
the HCT-116 cells following treatment with GT3. Activation of the cells with the calcium ionophore A23187 
and the addition of exogenous AA was carried out, and the lipids were analyzed by LC/MS/MS. The 
amount of 13-HODE in the HCT-116 cells was determined by stand curve analysis. The amount of 13-
HODE in HCT-116 cells show a statistically significant decrease in the GT3-treated sample compared 
with the vehicle (n=7; p = 0.0092).  Statistical differences were determined by paired t-test.  p values < 
0.05 were determined statistically significant. p values were obtained at 95% confidence level.  Error bars 
are representative of SEM of sample. 
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Figure 27.  The effect of GT3 on the amount of 13-HODE in HCT-116 cells as analyzed by the ELISA 
method.  HCT-116 cells were treated with and without 5 M GT3 for 24 hours. The lipid content was 
isolated from the HCT-116 cells following treatment with GT3.  Activation of the cells with the calcium 
ionophore A23187 and the addition of exogenous AA was carried out, and the lipids were analyzed by the 
ELISA method. The amount of 13-HODE in the HCT-116 cells was determined by stand curve analysis. 
The amount of 13-HODE in HCT-116 cells show a statistically significant decrease in the GT3-treated 
sample compared with the vehicle (n=7; p = 0.015).  Statistical differences were determined by paired t-
test.  p values < 0.05 were determined statistically significant. Error bars are representative of SEM of 
sample. 
 
GT, ATGT, AT, nor GT3 Regulate the Production of 15-HETE in HCT-116 Cells. 
The amount of 15-HETE produced in HCT-116 cells following treatment with 5 
µM GT shows no significant difference as compared with the vehicle (Figure 28; p = 
0.081).  In addition, the production of 15-HETE following treatment with 5 µM ATGT 
shows no significant difference as with the vehicle (Figure 29; p = 0.39).  Further, 
treatment of HCT-116 cells with 5 µM AT and 5 µM GT3 shows no statistical difference 
in the amount of 15-HETE as compared with the vehicle (Figures 30 and 31) with p 
values of 0.12 and 0.21, respectively.  These data indicate that neither GT, ATGT, AT, 
nor GT3 significantly regulate the production of 15-HETE in HCT-116 cells after 
activation of the LOX pathway with the calcium ionophore A23187 and addition of 
exogenous AA to the cells.  
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Figure 28.  The effect of GT on the amount of 15-HETE in HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM GT for 24 hours.  The lipid content was isolated from 
the HCT-116 cells following treatment with GT.  Activation of cells with the calcium ionophore A23187 and 
the addition of exogenous AA were carried out, and the lipids were analyzed by LC/MS/MS. The amount 
of 15-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 15-HETE in 
HCT-116 cells shows no statistical difference between the GT-treated sample and the vehicle-treated 
sample (n =10; p = 0.081). Statistical differences were determined by paired t-test.  p values < 0.05 were 
determined statistically significant. p values were obtained at 95% confidence level.  Error bars are 
representative of SEM of sample. 
 
 
 
Figure 29.  The effect of ATGT on the amount of 15-HETE in HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM ATGT for 24 hours.  The lipid content was isolated 
from HCT-116 cells following treatment with ATGT Activation of cells with the calcium ionophore A23187 
and the addition of exogenous AA was carried out, and the lipids were analyzed by LC/MS/MS.  The 
amount of 15-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 15-
HETE in HCT-116 cells shows no statistical difference between the ATGT-treated sample and the 
vehicle-treated sample treated (n =8; p = 0.39). Statistical differences were determined by paired t-test.  p 
values < 0.05 were determined statistically significant. p values are obtained at 95% confidence level.  
Error bars are representative of SEM of sample. 
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Figure 30.  The effect of AT on the amount of 15-HETE of HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM AT for 24 hours.  The lipid content was isolated from 
the HCT-116 cells following treatment with AT. Activation of cells with the calcium ionophore A23187 and 
the addition of exogenous AA were carried out, and the lipids were analyzed by LC/MS/MS.  The amount 
of 15-HETE in HCT-116 cells was determined by stand curve analysis. The amount of 15-HETE in HCT-
116 cells shows no statistical difference between the AT-treated sample and the vehicle-treated sample 
(n =8; p = 0.12). Statistical differences were determined by paired t-test.  p values < 0.05 were 
determined statistically significant. p values are obtained at 95% confidence level.  Error bars are 
representative of SEM of sample. 
 
 
Figure 31.  The effect of GT3 on the amount of 15-HETE of HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM GT3 for 24 hours.  The lipid content was isolated from 
the HCT-116 cells following treatment with GT3. Activation of cells with the calcium ionophore A23187 
and the addition of exogenous AA were carried out, and the lipids were analyzed by LC/MS/MS.  The 
amount of 15-HETE in CT-116 cells was determined by stand curve analysis. The amount of 15-HETE in 
HCT-116 cells shows no statistical difference between the GT3-treated sample and the vehicle-treated (n 
=8; p = 0.21). Statistical differences were determined by paired t-test.  p values < 0.05 were determined 
statistically significant. p values are obtained at 95% confidence level.  Error bars are representative of 
SEM of sample. 
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ATGT or GT3 Decrease the Production of 12-HETE in HCT-116 Cells after LOX 
Activation while AT Increases the Production but GT Does not Change the Production 
of 12-HETE.   
The amount of 12-HETE produced in HCT-116 cells after treatment with GT, AT, 
ATGT, and GT3 followed by activation of calcium ionophore and addition of exogenous 
AA was measured.  The production of 12-HETE in HCT-116 cells after treatment with 5 
µM GT did not show a statistical difference as compared with the vehicle (Figure 32; p = 
0.47).  Interestingly, treatment of HCT-116 cells with 5 µM ATGT significantly decreases 
the production of 12-HETE in HCT-116 cells as compared with the vehicle (Figure 33; p 
= 0.024).  However, treatment of the cells with 5 µM AT significantly increased the 
production of 12-HETE in HCT-116 cells as compared with the vehicle (Figure 34; p = 
0.034).   In addition, treatment of the HCT-116 cells with 5 µM GT3 significantly 
decreased the production of 12-HETE as compared with the vehicle (Figure 35; p = 
0.027).  These data indicate that the activity of the 12-LOX is decreased by ATGT 
mixture and GT3 treatments. 
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Figure 32.  The effect of GT on the amount of 12-HETE in HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM GT for 24 hours.  The lipid content was isolated from 
the HCT-116 cells following treatment with GT. Activation of cells with the calcium ionophore A23187 and 
the addition of exogenous AA was carried out.   The lipids were analyzed by LC/MS/MS. The amount of 
12-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 12-HETE in HCT-
116 cells treated shows no statistical difference between the GT-treated sample and the vehicle-treated 
sample (n =10; p = 0.47). Statistical differences were determined by paired t-test.  p values < 0.05 were 
determined statistically significant.  p values are obtained at 95% confidence level.  Error bars are 
representative of SEM of sample. 
 
 
 
Figure 33.  The effect of ATGT on the amount of 12-HETE in HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM ATGT for 24 hours.  The lipid content was isolated 
from the HCT-116 cells following treatment with ATGT. Activation of cells with the calcium ionophore 
A23187 and the addition of exogenous AA were carried out.  The lipids were analyzed by LC/MS/MS.  
The amount of 12-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 
12-HETE in HCT-116 cells show a statistically significant decrease in the ATGT-treated sample compared 
with the vehicle treated sample (n =8; p = 0.024). Statistical differences were determined by paired t-test.  
p values < 0.05 were determined statistically significant. p values are obtained at 95% confidence level.  
Error bars are representative of SEM of sample. 
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Figure 34.  The effect of AT on the amount of 12-HETE of HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM AT for 24 hours.  The lipid content was isolated from 
the HCT-116 cells following treatment with AT. Activation of cells with the calcium ionophore A23187 and 
the addition of exogenous AA were carried out.  The lipids were analyzed by LC/MS/MS.  The amount of 
12-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 12-HETE in HCT-
116 cells show a statistically significant increase in the AT-treated sample compared with the vehicle 
treated sample (n =7; p = 0.034). Statistical differences were determined by paired t-test.  p values < 0.05 
were determined statistically significant.  p values are obtained at 95% confidence level.  Error bars are 
representative of SEM of sample. 
 
 
 
Figure 35.  The effect of GT3 on the amount of 12-HETE in HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM GT3 for 24 hours.  The lipid content was isolated from 
the HCT-116 cells following treatment with GT3.   Activation of cells with the calcium ionophore A23187 
and the addition of exogenous AA was carried out, and the lipids were analyzed by LC/MS/MS.  The 
amount of 12-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 12-
HETE in HCT-116 cells show a statistically significant decrease in the GT3-treated sample compared with 
the vehicle (n =8; p = 0.027). Statistical differences were determined by paired t-test.  p values < 0.05 
were determined statistically significant. p values are obtained at 95% confidence level.  Error bars are 
representative of SEM of sample. 
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5-HETE is Decreased by GT3, Increased by AT and not Changed by GT or ATGT 
Treatments after Activation of LOX Pathway by the Calcium Ionophore (A23187) and 
Arachidonic Acid. 
The amount of 5-HETE produced in HCT-116 cell following treatments with 
vitamin E isoforms, GT, AT, GT3, and ATGT mixture and further activation of the cells 
with calcium ionophore and addition of AA was also investigated.  5-HETE in HCT-116 
cells is not significantly decreased by treatment with 5 µM GT as compared with the 
vehicle (Figure 36; p = 0.11).  Treatment of HCT-116 cells with 5 µM ATGT did not 
significantly decrease the production of 5-HETE in HCT-116 cells as compared with the 
vehicle (Figure 37; p = 0.11). However, treatment of HCT-116 cells with 5 µM AT 
significantly increased the production of 12-HETE as compared with the vehicle (Figure 
38; p = 0.037).  In addition, 5 µM GT3 significantly decreased the production of 5-HETE 
in HCT-116 cells (Figure 39; p = 0.046).  These data indicate that only GT3 allowed for 
a significant decrease in the production of 5-HETE production after activation of HCT-
116 cells with the calcium ionophore and the addition of exogenous AA.  The increase 
in the production of 5-HETE by AT after activation of HCT-116 cells with calcium 
ionophore and addition AA suggest that the 5-LOX enzyme is still active allowing for the 
production of 5-HETE. 
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 Figure 36.  The effect of GT on the amount of 5-HETE of HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM GT for 24 hours.  The lipid content was isolated from 
the HCT-116 cells following treatment with GT.  Activation with calcium ionophore and the addition of 
exogenous AA were carried out. The lipids were analyzed by LC/MS/MS.   The amount of 5-HETE in the 
HCT-116 cells was determined by stand curve analysis. The amount of 5-HETE in HCT-116 cells shows 
no statistical difference between the GT-treated sample and the vehicle-treated sample (n =11; p = 0.11). 
Statistical differences were determined by paired t-test.  p values < 0.05 were determined statistically 
significant.  p values are obtained at 95% confidence level.  Error bars are representative of SEM of 
sample. 
 
 
Figure 37.  The effect of ATGT on the amount of 5-HETE of HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM ATGT for 24 hours.  The lipid content was isolated 
from the HCT-116 cells following treatment with ATGT.  Activation with calcium ionophore and the 
addition of exogenous AA were carried out. The lipids were analyzed by LC/MS/MS.  The amount of 5-
HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 5-HETE in HCT-116 
cells shows no statistical difference between the ATGT-treated sample and the vehicle-treated sample 
(n= 9; p = 0.11). Statistical differences were determined by paired t-test.  p values < 0.05 were 
determined statistically significant.   p values are obtained at 95% confidence level.  Error bars are 
representative of SEM of sample. 
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Figure 38.  The effect of AT on the amount of 5-HETE in HCT-116 cells as analyzed by LC/MS/MS. HCT-
116 cells were treated with and without 5 µM AT for 24 hours.  The lipid content was isolated from the 
HCT-116 cells following treatment with AT.  Activation of cells with the calcium ionophore A23187 and the 
addition of exogenous AA was carried out, and the lipids were analyzed by LC/MS/MS.  The amount of 5-
HETE in the HCT-116 cells was determined by stand curve analysis.  The amount of 5-HETE in HCT-116 
cells shows a statistically significant increase in the AT-treated sample compared with the vehicle (n =8; p 
= 0.037). Statistical differences were determined by paired t-test.  p values < 0.05 were determined 
statistically significant.   p values are obtained at 95% confidence level.  Error bars are representative of 
SEM of sample. 
 
 
Figure 39.  The effect of GT3 on the amount of 5-HETE in HCT-116 cells as analyzed by LC/MS/MS. 
HCT-116 cells were treated with and without 5 µM GT3 for 24 hours.  The lipid content was isolated from 
the HCT-116 cells following treatment with GT3.   Activation of cells with the calcium ionophore A23187 
and the addition of exogenous AA was carried out, and the lipids were analyzed by LC/MS/MS.  The 
amount of 5-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 5-HETE 
in HCT-116 cells shows a statistically significant decrease in the GT3-treated sample compared with the 
vehicle (n =7; p = 0.046). Statistical differences were determined by paired t-test.  p values < 0.05 were 
determined statistically significant.   p values are obtained at 95% confidence level.  Error bars are 
representative of SEM of sample. 
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CHAPTER 4 
DISCUSSION 
In this study we found that, under both, physiological conditions and LOX 
induction by calcium ionophore A23187, each isoform of vitamin E tested (GT, AT, GT3 
and ATGT mixture) exhibited different effects on the production of polyunsaturated fatty 
acid metabolites (LOX metabolites).  Since these metabolites (13-HODE, 15-HETE,12-
HETE, and 5-HETE) have previously been associated with colorectal cancer 
development52,44,67, we were interested in determining whether vitamin E isoforms have 
the ability to regulate the LOX pathway through the production of the LOX metabolites.  
Under normal physiological conditions, we discovered that GT increases the 
amount of 13-HODE (Figure 6), and decreases the amount of 12-HETE in the media of 
HCT-116 cells (Figure 14), but does not regulate the amount of 15-HETE or 5-HETE in 
the media of HCT-116 cells (Figures 10 and 18).   
NSAIDs like sulindac and NS398 enhance 13-HODE production in colorectal 
cancer cells53,54.   GT mirrors this function of NSAIDs in colorectal cancer cells. The 
flavonoid baicalein and sulindac are 12-LOX inhibitors and thereby inhibiting the 
production of 12-HETE in colorectal cancer cells42,41.  GT also mirrors the function of 
12-LOX inhibitors under physiological conditions as it down regulates the production of 
12-HETE into the media of HCT-116 cells treated under physiological conditions (Figure 
14).   
69 
 
We found that under physiological conditions, the ATGT mixture (95% GT and 
5% AT) increases the production of 13-HODE secreted into the media from HCT-116 
cells (Figure 7).  However, the ATGT mixture does not regulate the amount of 15-HETE 
(Figure 11), 12-HETE (Figure 15), or 5-HETE (Figure 19) produced and secreted in the 
media of HCT-116 cells.   
This study demonstrates that, under normal physiological conditions, AT 
decreases the ability of GT to regulate the production of 13-HODE and 12-HETE 
secreted into the HCT-116 media. This is evidenced by the fact that the ATGT mixture 
demonstrated less than a 2 fold increase in 13-HODE compared to the vehicle (Figure 
7) while pure GT demonstrated a 5 fold increase in 13-HODE compared to the vehicle 
(Figure 6).  Further, the ATGT mixture (Figure 15) did not significantly decrease the 
amount of 12-HETE secreted in the HCT-116 media as did pure GT (Figure 14).   Pure 
AT did not significantly regulate the production of 13-HODE (Figure 8) or 12-HETE 
(Figure 16) under physiological conditions.  In fact, AT under physiological conditions 
had no effect on any of the metabolites (13-HODE (Figure 8), 12-HETE (Figure 16), 5-
HETE (Figure 12) or 5-HETE (Figure 20). 
Our study shows that, under normal physiological conditions, GT3 does not 
significantly affect the amount of 13-HODE (Figure 9), 15-HETE (Figure 13), 12-HETE 
(Figure 17), and 5-HETE (Figure 21) secreted in the media of the HCT-116 cells.   
Hence, under normal physiological conditions, GT shows a greater effect in 
regulating the production of polyunsaturated fatty acid metabolites as it increases the 
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amount of 13-HODE and decreases the amount of 12-HETE secreted in the media of 
the HCT-116 cells. 
When examining the production of the metabolites under the LOX activation 
conditions (addition of the calcium ionophore A23187 with exogenous AA to the cells 
post treatment), we observed that the 12-LOX enzyme was no longer active. The 
production of 12-HETE (Figure 32) in the cells as compared with the vehicle were not 
significantly increased.  A possible reason for the reduction may be a lack of substrate 
availability or enzyme activity.  We would expect that if the 12-LOX enzyme was still 
active, the amount of 12-HETE produced after activation of cells with calcium ionophore 
A23187 and addition of AA should increase following treatment with GT.  However, the 
amount of 12-HETE produced in the GT-treated samples did not significantly change as 
compared with the vehicle under conditions that would activate the LOX pathway, which 
suggests that the 12-LOX activity is reduced by the GT pretreatment.  The decrease in 
activity of the 12-LOX enzyme by GT was also observed as the amount of 12-HETE 
produced and secreted in the media under physiological conditions was significantly 
lower when compared with the vehicle (Figure 14).  
  As previously observed in the media (Figure 11 and 19), ATGT did not 
significantly decrease the amount of 15-HETE (Figure 29) and 5-HETE (Figure 37) in 
HCT-116 cells under LOX Activation conditions, thus confirming that ATGT does not 
significantly regulate the amount of 15-HETE or 5-HETE in HCT-116 cells neither under 
physiological conditions nor with LOX activation by the calcium ionophore A23187 and 
additional AA.   
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In addition, AT was observed to significantly increase the production of 12-HETE 
(Figure 34) and 5-HETE (Figure 38) after addition of calcium ionophore A23187 and 
exogenous AA to the cells, although under normal physiological conditions AT did not 
significantly increase the amount of 12-HETE or 5-HETE produced into the media 
(Figures 16 and 20).  It is possible that under normal physiological conditions, there is 
not enough substrate (AA) present in the cells to be metabolized by 12-LOX or 5-LOX 
enzyme after treatment with AT.   It is also possible that the addition of calcium 
ionophore A23187 activated the LOX pathway enhancing the activity of the 12-LOX or 
5-LOX enzyme and allowing AT to produce more 12-HETE or 5-HETE in the cells. 
Further, we observed that GT3 has no effect on LOX metabolism under 
physiological conditions, but significantly decreases the production of 13-HODE 
(Figures 26 and 27), 12-HETE (Figure 35), and 5-HETE (Figure 39) conditions of LOX 
activation.  Thus, it is possible that the activity of 15-LOX-1, 12-LOX, and 5-LOX in 
HCT-116 cells are reduced by GT3 treatment.  The addition of AA to the cells will 
provide the substrate necessary to produce the 12-HETE and 5-HETE.  It is also 
possible that GT3 prevents the activation of the LOXs on AA.  Additional studies are 
necessary to determine the role that GT3 plays on the statistically significant inhibition 
of 12-HETE and 5-HETE production following the activation of the LOX pathway with 
the calcium ionophore A23187 and AA.   
Finally, we found that none of the vitamin E isoforms tested (GT, AT, ATGT and 
GT3) significantly regulates the production of 15-HETE in HCT-116 cells either under 
normal physiological conditions or LOX activation conditions. 
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In summary: 
Table 1.  Amount of 13-HODE, 15-HETE, 12-HETE, and 5-HETE Secreted into the 
Media of HCT-116 Cells after Treatment of Cells with 5 µM GT, AT, ATGT, or GT3 
under Physiological Conditions. 
Vitamin E 
isoforms 
13-HODE 15-HETE 12-HETE 5-HETE 
GT Increase Not statistically 
significant 
Decrease Not 
statistically 
significant 
ATGT Increase Not statistically 
significant 
Not statistically 
significant 
Not 
statistically 
significant 
AT Not statistically 
significant 
Not statistically 
significant 
Not statistically 
significant 
Not 
statistically 
significant 
GT3 Not statistically 
significant 
Not statistically 
significant 
Not statistically 
significant 
Not 
statistically 
significant 
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Table 2. Production of 13-HODE, 15-HETE, 12-HETE, and 5-HETE Following 24 hour 
Pretreatment of HCT-116 Cells with 5 µM GT, AT, ATGT, or GT3 and Subsequent LOX 
Activation with the Addition of Calcium Ionophore A23817and Exogenous Arachidonic 
Acid. 
Vitamin E 
isoforms 
13-HODE 15-HETE  12-HETE 5-HETE 
GT Not statistically 
significant 
Not statistically 
significant 
Not statistically 
significant 
Not statistically 
significant 
ATGT Not statistically 
significant 
Not statistically 
significant 
Decrease Not statistically 
significant 
AT Not statistically 
significant 
Not statistically 
significant 
Increase Increase 
GT3 Decrease Not statistically 
significant 
Decrease Decrease 
 
In conclusion, the vitamin E isoforms, GT, GT3, AT as well as ATGT mixture did 
not have the same effect on the production of polyunsaturated fatty acid, 13-HODE, 15-
HETE, 12-HETE, and 5-HETE under physiological conditions or LOX activation 
conditions.  Under normal physiological conditions, GT is the best isoform of vitamin E 
as it increases the amount of 13-HODE and decreases 12-HETE in media of HCT-116 
cells.  It was also determined that under normal physiological conditions, AT has the 
ability to decrease the activity of GT in regulating the production of 13-HODE and 12-
HETE in the media of HCT-116 cells. 
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Analytical Problems and Future Directions 
Problems.  Random error was observed in the data collected during this project.  
Hence, high number of replicates was done to enhance the precision of the data.  A 
paired t-test was used to examine whether the metabolites obtained from the vehicle 
and treated samples are statistically significant.  
Analytes obtained from extract initially precipitated at higher pH values (5.5-7.4) 
when dissolved in the following solvent system: ethanol, methanol, hexane, and 
ammonium acetate.  The pH of the solution was therefore decreased to about 3.5-4.0 
which prevented precipitation of the analyte in the solvent (methanol) used for 
dissolving these analytes. This is because the analytes obtained after extraction are 
fatty acids and exhibit high solubility as the pH of the solution is decreased. 
Future Work.  We would like to investigate the concentrations of HETEs (12-
HETE, 15-HETE, and 5-HETE) and 13-HODE when LA is added during the isolation 
rather than AA.  This experiment would be aimed at determining if reduction of 13-
HODE production observed with GT and ATGT in the cells is due to lack of substrate or 
reduced enzyme activity. 
We would also like to investigate the concentrations of HETEs (12-HETE, 15-
HETE, and 5-HETE) and 13-HODE in the presence of chemical inhibitors for 15-LOX 
(e.g. 6, 11-dihydro-[1]benzothiopyrano[4,3-b]indole(PD146176)), 12-LOX (e.g. caffeic 
acid), and 5-LOX (e.g. AA861). These experiments would enable us to know the 
predominant LOX pathway that causes cell death in colorectal cancer cells. 
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APPENDICES 
Appendix A 
Tables of Confidence Limits and p-values 
Table 3.  Confidence Intervals (CI) for 13-HODE, 15-HETE, 12-HETE, and 5-HETE in 
the Media of HCT-116 Cells Obtained at 95% Confidence Level 
Vitamin E 
isoforms 
13-HODE 15-HETE 12-HETE 5-HETE 
GT Figure 6 
CI = - 5.5 to 
0.40 
Figure 10 
CI = - 0.37 to 
0.27 
Figure 14 
CI = 0.23 to 0.69 
Figure 18 
CI = -1.0 to 
1.0 
ATGT Figure 7 
CI = - 1.4 to 
0.13 
Figure 11 
CI = - 0.60 to 
1.17 
Figure 15 
CI = - 0.50 to 
0.32 
Figure 19 
CI = - 0.60 to 
1.2 
AT Figure 8 
CI = - 1.1 to 
0.20 
Figure 12 
CI = - 0.10 to 
0.10 
Figure 16 
CI = - 0.079 to 
0.070 
Figure 20 
CI = - 0.44 to 
0.079 
GT3 Figure 9 
CI = - 0.39 to 
0.53 
Figure 13 
CI = - 0.37 to 
0.27 
Figure 17 
CI = - 0.64 to 1.0 
Figure 21 
CI = - 0.57 to 
1.1 
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Table 4.  Confidence Intervals (CI) for 13-HODE, 15-HETE, 12-HETE, and 5-HETE in 
HCT-116 Cells Obtained at 95% Confidence Level 
 
Vitamin E 
isoforms 13-HODE 15-HETE 12-HETE 5-HETE 
GT Figure 23 
CI = - 0.23 to 
0.18 
Figure 28 
CI = -0.043 to 
0.22 
Figure 32 
CI = - 0.44 to 
0.47 
Figure 36 
CI =  - 0.57 to 
2.14 
ATGT Figure 24 
CI = - 0.31 to 
0.10 
Figure 29 
CI = - 0.19 to 
0.15 
Figure 33 
CI = 0.0072 to 
0.94 
Figure 37 
CI = - 0.47 to 
1.7 
AT Figure 24 
CI = - 0.19 to 
0.071 
Figure 30 
CI = - 0.081 to 
0.024 
Figure 34 
CI = - 0.83 to 
0.04 
Figure 38 
CI = -0.44 to 
0.079 
GT3 Figure 26 
CI = 0.031 to 
0.23 
Figure 31 
CI = - 0.083 to 
0.18 
Figure 35 
CI = - 0.0079 to 
0.88 
Figure  39 
CI = - 0.41 to 
4.0 
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Table 5.  Probability Test Values (p-value or p) of 13-HODE, 15-HETE, 12-HETE, and 
5-HETE in the Media of HCT-116 Cells Obtained at 95% Confidence Level 
Vitamin E 
isoforms 
13-HODE 15-HETE 12-HETE 5-HETE 
GT Figure  6 
p = 0.038 
Figure 10 
p  = 0.36 
Figure 14 
p = 0.0014 
Figure 18 
p  = 0.49 
ATGT Figure 7 
p = 0.045 
Figure 11 
p = 0.25 
Figure 15 
p = 0.30 
Figure 19 
p = 0.24 
AT Figure 8 
p = 0.067 
Figure 12 
p  = 0.49 
Figure16 
p = 0.45 
Figure 20 
p  = 0.072 
GT3 Figure 9 
p = 0.37 
Figure 13 
p = 0.47 
Figure 17 
p = 0.29 
Figure 21 
p = 0.24 
 
Table 6.  Probability Test Values (p-value or p) of 13-HODE, 15-HETE, 12-HETE, and 
5-HETE in HCT-116 Cells Obtained at 95% Confidence Level 
Vitamin E 
isoforms 
13-HODE 15-HETE 12-HETE 5-HETE 
GT Figure 23 
p = 0.39 
Figure 28 
p = 0.081 
Figure 32 
p = 0.47 
Figure 36 
p = 0.11 
ATGT Figure 24 
p = 0.14 
Figure 29 
p  = 0.39 
Figure 33 
p = 0.024 
Figure 37 
p = 0.11 
AT Figure 25 
p = 0.16 
Figure 30 
p = 0.12 
Figure 34 
p = 0.034 
Figure 38 
p = 0.037 
GT3 Figure 26 
p = 0.0092 
Figure 31 
p = 0.21 
Figure 35 
p = 0.027 
Figure 39 
p = 0.046 
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Table 7.  Confidence Intervals (CI) and Probability Test Values (p-value or p) for the 
Amount of 13-HODE in HCT-116 Cells Using ELISA Method. 
Vitamin E isoforms 13-HODE 
GT Figure 22 
p = 0.096 
CI = -0.033 to 0.0081 
GT3 Figure 27 
p = 0.015 
CI = 0.0039 to 0.052 
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Appendix B 
Buffers and Solutions 
1. PBS: Prepared using 8 g sodium chloride, 0.2 g potassium chloride, 
0.2 g potassium dihydrogen phosphate, and 1.15 g disodium hydrogen 
phosphate in 1 L of distilled water. 
2. Lysis buffer: Prepared using 98 mL of PBS, 1 mL of 10% triton X-100, 1 mL of 
10% sodium dodecyl sulphate. 
3. Calcium chloride (1 mM): 0.0147 g of calcium chloride dihydrate was weighed 
and dissolved in 100 mL of PBS. 
4. Calcium ionophore (1 mM): 0.001 g of calcium ionophore was dissolved in 2 mL 
of PBS solution. 
5. 0.2 N HCl: 1.65 mL of 12.1 N HCl was diluted to 100 mL with deionised water. 
6. Wash Buffer: 5 mL of the supplied concentrate was diluted with 95 mL of 
deionized water.  
7. Conjugate (1:10) dilution: 50 µL of the supplied conjugate was diluted with 450 
mL of standard diluents (assay buffer).  
8. Arachidonic acid (10000 µM): 10000 µM was prepared from 0.8210 M 
arachidonic acid stock solution in ethanol. 
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Appendix C 
List of Instruments 
1. HP- 8452A diode array spectrophotometer 
2. UV-VIS spectrophotometer plate reader (Molecular devices, Spectra Max Plus 
384).  
3.   Shimadzu IT-TOF LC/MS/MS 
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Appendix D 
Lists of Abbreviations 
AA                           - arachidonic acid 
AA-861                    - 2-(12-Hydroxydodecane-5, 10-diynyl)-3, 5, 6-trimethyl-p   
                                 benzoquinone                                             
AT                           - alpha tocopherol 
AT3                         - alpha tocotrienol 
ATGT                      - alpha tocopherol – gamma tocopherol mixture 
Bcl-2                        - B-cell lymphoma 2 
BHPP                      - N-benzyl-N-hydroxy-5-phenylpentamide 
BRL49653               - rosiglitazone 
Cdk                         - cyclin-dependent kinases  
COX-2                    - cyclooxygenase-2 
DNA                        - deoxyribonucleic acid  
ELISA                     - enzyme-linked immunosorbent assay 
FBS                         - fetal bovine serum 
G1                            - gap 1 
G2                                          - gap 2 
GT                           - gamma tocopherol 
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GT3                         - gamma tocotrienol 
HCl                          - hydrochloric acid 
HETE                      - hydroxyeicosatetraenoic acid 
HODE                     - hydroxyoctadecadienoic acid  
13-HODE                -13-hydroxyoctadecadienoic acid 
15-HETE                 -15-hydroxyoctadecadienoic acid  
12-HETE                 -12-hydroxyeicosatetraenoic acid 
IT-TOF                    - ion trap time of fight 
IU                            - international unit 
Kg                           - kilogram 
LOX                         - lipoxygenase 
LC/MS/MS              - liquid chromatography/tandem mass spectrometry  
LA                           - Linoleic acid 
µM                           - micromolar 
Max                         - maximum 
M                             - mitotic 
MD                          - Maryland 
mg                           - milligram 
min                          - minutes 
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mL                           - milliliter 
mM                          - millimolar 
MK 886                   - 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-α,α-                                                                                                                                                     
                                  dimethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid  
M                           - micromolar 
nM                           - nanometer 
NSAID                     - non-steroidal anti-inflammatory drug 
NY-                          -New York 
P                             - protein 
PAH                        - polycyclic aromatic hydrocarbons 
PBS                        - phosphate buffered saline 
PG                                        - prostaglandins  
PPAR γ-                  - peroxisome proliferator-activated receptor γ 
R                             - rectus 
RB                           - retinoblastoma 
S                             - synthesis 
UV-VIS                    - ultraviolet-visible  
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